The Guardian view on de-extinction: Jurassic Park may be becoming reality
By Editorial,
The Guardian
| 08. 19. 2022
We should be keeping endangered species alive rather than bringing animals back from extinction
"tasmanian tiger" by nicolas.boullosa is licensed under CC BY 2.0.
The last official sighting of a Tasmanian tiger in the wild occurred in 1930, when it was shot by a farmer. The marsupials, formally known as thylacines, were hunted to extinction by European settlers who considered them a threat to their sheep and poultry. However, the 6ft-long creatures may reappear if a group of biotechnologists have their way.
The company Colossal Biosciences, along with researchers from the University of Melbourne, plans to “de-extinct” the thylacine by using gene-editing technology. Australia has the fastest rate of mammal extinction in the world; disappearances are down to the arrival of foreign species and wildfires linked to the climate crisis. Scientists argue that in Tasmania the loss of the thylacine left the numbers of smaller marsupials unchecked, leading to over-grazing and threatening a fragile ecological balance.
If it all sounds like a plot line from Jurassic Park, then that is because the science behind the resurrection plan provided the movie’s inspiration. Last year Colossal, co-founded by a Harvard geneticist, raised...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...